Indivior (INDV) AI Stock Analysis

• Market Cap: $3.03B
• Dividend Yield: N/A
• Average Volume (3M): 3.75M
• Price to Earnings (P/E): 34.3
• Beta (1Y): 0.60
• Revenue Growth: 2.27%
• EPS Growth: N/A
• Country: US
• Employees: 1,030
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.51
• Shares Outstanding: 124,769,820
• 10 Day Avg. Volume: 2,254,614
• 30 Day Avg. Volume: 3,746,243
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 1.46
• Enterprise Value/Gross Profit: 1.74
• Enterprise Value/Ebitda: 6.28
• 1Y Price Target: $207.86
• Price Target Upside: 765.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 58 Neutral
• Price Target: $1,288.00 ▲(5264.43% Upside)

Indivior's overall stock score is driven by strong earnings call performance and positive corporate events, offset by financial instability and lack of technical analysis data. The company's strategic initiatives and improved guidance provide a positive outlook, but financial and valuation concerns remain.

Positive Factors

Financial Stability

Indivior is well-positioned to fund any legal obligations, reinvest in its lead assets, and pursue share repurchases or accretive transactions with $538M in cash and investments.

Leadership and Growth Potential

Indivior's established leadership in the OUD sector and the potential for significant growth in the LAI category could see both Sublocade and Brixadi flourish.

Operational Efficiency

The company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.

Negative Factors

Competitive Pressure

Sublocade was ultimately $100M below initial 2024 guidance from competitor Brixadi share gains and also CJS funding disruption.

Market Headwinds

CJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.

Spending and Efficiency

The company is believed to be overspending on G&A, and the operational structure could become much more efficient, enhancing future profitability.

Indivior Business Overview & Revenue Model

Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

How the Company Makes Money

Indivior makes money primarily through the sale of its pharmaceutical products, particularly those targeting opioid addiction treatment. The company's revenue model is based on the commercialization of its proprietary medications, including Suboxone Film and Sublocade, which are sold to healthcare providers, pharmacies, and government agencies. Indivior's earnings are significantly influenced by its market share in the addiction treatment sector, ongoing clinical trials, and regulatory approvals that allow for the expansion of its product offerings. Additionally, partnerships with healthcare organizations and distribution agreements play a crucial role in broadening the reach of its products and enhancing revenue streams.

Indivior Financial Statement Overview

Summary

Indivior shows strong revenue growth and improving profitability, but faces significant balance sheet challenges with negative equity and high leverage. Cash flow improvements are promising, yet operational efficiency needs enhancement.

Income Statement

Indivior's income statement shows a strong gross profit margin of 83.99% TTM, indicating efficient cost management. The net profit margin improved to 10.90% TTM, reflecting enhanced profitability compared to previous periods. Revenue growth rate of 20.4% TTM is robust, signaling positive sales momentum. However, EBIT and EBITDA margins, while improved, remain moderate at 21.98% and 23.25% TTM, respectively, suggesting room for operational efficiency improvements.

Balance Sheet

The balance sheet reveals a concerning negative stockholders' equity of $-258 million TTM, leading to a negative debt-to-equity ratio, which indicates financial instability. The return on equity is also negative, highlighting profitability challenges. The equity ratio is not calculable due to negative equity, underscoring the need for capital restructuring.

Cash Flow

Cash flow analysis shows a significant improvement in free cash flow growth at 43.37% TTM, indicating better cash generation capabilities. The operating cash flow to net income ratio is low at 0.22 TTM, suggesting limited cash conversion efficiency. The free cash flow to net income ratio is strong at 80.08% TTM, reflecting effective cash management despite operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.17B	1.19B	1.09B	884.63M	777.48M	689.68M
Gross Profit	986.00M	957.00M	907.00M	715.75M	639.87M	573.49M
EBITDA	273.00M	84.00M	68.61M	-44.18M	233.93M	-128.98M
Net Income	128.00M	2.00M	2.00M	-52.04M	205.00M	-157.76M
Balance Sheet
Total Assets	1.45B	1.32B	1.95B	1.78B	1.83B	1.53B
Cash, Cash Equivalents and Short-Term Investments	510.00M	320.00M	410.00M	897.83M	1.10B	858.00M
Total Debt	366.00M	375.00M	282.00M	278.50M	285.44M	285.00M
Total Liabilities	1.71B	1.67B	1.95B	1.73B	1.63B	1.45B
Stockholders Equity	-258.00M	-348.00M	67.90M	51.28M	202.60M	82.00M
Cash Flow
Free Cash Flow	189.00M	7.00M	-368.00M	-9.82M	313.55M	-210.00M
Operating Cash Flow	236.00M	36.00M	-315.00M	-3.93M	346.97M	-205.73M
Investing Cash Flow	20.00M	69.00M	-100.36M	-218.95M	-13.76M	-4.26M
Financing Cash Flow	-50.00M	-102.00M	-46.00M	-98.18M	-92.39M	-10.66M

Indivior Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDV, the sentiment is Positive. The current price of 24.01 is above the 20-day moving average (MA) of 23.21, above the 50-day MA of 18.78, and above the 200-day MA of 12.94, indicating a bullish trend. The MACD of 1.63 indicates Positive momentum. The RSI at 77.28 is Negative, neither overbought nor oversold. The STOCH value of 57.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDV.

Indivior Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	76 Outperform	$2.53B	39.43	6.38%	―	5.55%	1145.24%
AMPH	68 Neutral	$1.42B	11.46	18.32%	―	1.37%	-18.10%
ANIP	66 Neutral	$2.03B	―	-2.82%	―	38.68%	-160.14%
PCRX	61 Neutral	$1.20B	―	-15.57%	―	2.25%	-301.59%
INDV	58 Neutral	$3.03B	34.26		―	2.27%	―
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
EVO	41 Neutral	$1.24B	―	-16.34%	―	-1.03%	8.13%

Indivior Corporate Events

Indivior Launches Action Agenda for Business Enhancement

Indivior PLC has launched the Indivior Action Agenda, a multi-year operational roadmap to enhance its business potential and impact on opioid use disorder treatment. As part of Phase 1, the company is implementing initiatives to simplify its organization, including headcount reductions and real estate consolidations, expecting to incur restructuring charges of $39 to $50 million in 2025. Additionally, Indivior is exploring strategic alternatives for OPVEE® and its non-U.S. business, which could lead to further cost savings.

Indivior Updates CFO Employment Agreements

On August 20, 2025, Indivior PLC updated its employment agreements with CFO Ryan Preblick to align with current U.S. executive agreements, without altering his compensation or responsibilities. The new agreements include an annual base salary of $558,819, a cash bonus opportunity, and potential long-term incentive awards, reflecting the company’s commitment to maintaining competitive executive compensation structures.

Indivior Raises 2025 Guidance After Strong Q2 Results

On July 31, 2025, Indivior reported its second-quarter financial results, showing a total net revenue of $302 million, with SUBLOCADE net revenue increasing by 9% year-over-year. The company raised its full-year 2025 financial guidance due to better-than-expected performance, with expectations for total net revenue and adjusted EBITDA increasing significantly. Indivior is implementing Phase 1 of its Action Agenda to grow U.S. SUBLOCADE revenue and streamline operations, positioning itself for future growth. The company also announced its inclusion in the Russell Equity Indexes and completed its transition to trading exclusively on Nasdaq.

Indivior Appoints Tony Kingsley as Non-Executive Director

On June 24, 2025, Indivior PLC announced the appointment of Tony Kingsley as a non-executive director, effective July 1, 2025. Kingsley, an accomplished biopharmaceutical executive, is expected to bring significant commercial and clinical development experience to Indivior, enhancing its efforts to advance its mission and strengthen its position in delivering treatments for opioid use disorder. His appointment aligns with Indivior’s relationship agreement with affiliates of Oaktree Capital Management, and he will be compensated in line with other non-executive directors.